D-0726-2021 Class II Terminated
FDA drug recall D-0726-2021 was initiated by Novel Laboratories, Inc. D.B.A LUPIN on Jul 29, 2021 and is designated Class II. Reason for recall: Failed Stability Specification; Out of specification for Osmolarity The recall status is terminated (terminated Nov 14, 2022). Affected quantity: 20,814 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Aug 25, 2021
- Initiation Date
- Jul 29, 2021
- Termination Date
- Nov 14, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 20,814 bottles
Product description
GaviLyteTM - C PEG-3350 (240g) and Electrolytes for Oral Solution, USP with Flavor Pack Manufactured by Novel Laboratories, Inc. Somerset, NJ 08873, USA Manufactured for Lupin Pharmaceuticals, Inc. Baltimore, MD 21202 NDC 43386-060-19
Reason for recall
Failed Stability Specification; Out of specification for Osmolarity
Distribution pattern
Nationwide
Code information
Lot S001133, exp 7/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0726-2021
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026